日本薬理学会年会要旨集
Online ISSN : 2435-4953
WCP2018 (The 18th World Congress of Basic and Clinical Pharmacology)
セッションID: WCP2018_PO2-5-33
会議情報

Poster session
Consideration in developing new anti-inflammatory immune drugs- Soft regulation of inflammatory immune responses
Wei Wei
著者情報
会議録・要旨集 オープンアクセス

詳細
抄録

Inflammation reaction and immune response are inseparable at the levels of system, tissue, cell and molecule. Inflammatory immune responses (IIR) is defined a moderate or abnormal system responses of inflammatory immune related cells in responding to the internal and external environment changes of body. Inflammatory immune related cells (traditionally, e.g., macrophages, dendritic cells, T cells and B cells, etc., and non-traditionally, e.g., glial cells, endothelial cells, epithelial cells, fibroblasts, synovial cells and liver cells, etc.), and cytokines/receptor signal transduction involved in IIR. In current clinic drugs, such as inhibitors of COXs, inhibitors of TNF alpha, IL-6, IL-17, BAFF etc., traditional immunosuppressive drugs (e.g., methotrexate, leflunomide,) and novel kinase inhibitor(e.g., JAKs inhibitor), suppress enzyme activity, gene synthesis and transcription, cytokines and receptor signal, etc, respectively. These drugs restrain the excessive activation function of inflammatory immune related cells, but at the same time, also inhibit the physiological response of these cells to signaling molecules, which cause physiological function disorder of cells and tissues,increase the risks of serious adverse drug reaction including infection and cance. Soft regulation of inflammatory immune responses (SRIIR), that is regulating the activity of key molecules or interaction between molecules in cells and resulting in making excessive activation function back to normal physiological levels, is a novel direction in developing new anti-inflammatory immune drugs for the treatment of IIR related diseases.

Key words: inflammatory immune responses (IIR), soft regulation of inflammatory immune responses (SRIIR), development of new drugs

Foundation item:The project supported by the National Natural Science Foundation of China (No. 81330081 and 81673444).

Corresponding author: WEI Wei, E-mail: wwei@ahmu.edu.cn

Affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine,Hefei 230032, China

著者関連情報
© 2018 The Authors(s)
前の記事 次の記事
feedback
Top